Investor Relations
Kingston Biotechnology Research is a privately held biotech research organization advancing science through innovation in genomics, proteomics, and drug discovery.
Recent Milestones
CRISPR Therapeutics Pipeline Enters Phase I Trials
First-in-class gene editing therapy for sickle cell disease advances to human clinical trials following successful preclinical validation.
Proteomics Center Expansion Completed
New 15,000 sq ft facility with cryo-EM and next-generation mass spectrometry instruments operational.
Strategic Partnership with European Bioinformatics Institute
Collaborative agreement to develop open-source genomic analysis tools and share research datasets.
Financial Highlights
Board of Directors
Dr. Margaret Liu
Chairperson
Former CSO, Genentech
Dr. Robert Kessler
Director
Partner, Venrock Healthcare
Dr. Amara Osei
Director
Dean, Columbia School of Engineering
James Hartwell
Director
CEO, KBR
Investor Inquiries
For investor relations inquiries, financial reports, or partnership discussions, please contact our investor relations team.
Contact Investor Relations